Smyth Robert, Billatos Ehab
Department of Medicine, Section of Pulmonary, Critical Care and Occupational Medicine University of Iowa, Iowa City, IA 52242, USA.
Department of Medicine, Section of Pulmonary and Critical Care Medicine, Boston University, Boston, MA 02215, USA.
J Clin Med. 2024 Nov 27;13(23):7207. doi: 10.3390/jcm13237207.
Lung cancer is a major global health issue, with 2.21 million cases and 1.80 million deaths reported in 2020. It is the leading cause of cancer death worldwide. Most lung cancers have been linked to tobacco use, with changes in cigarette composition over the years contributing to shifts in cancer types and tumor locations within the lungs. Additionally, there is a growing incidence of lung cancer among never-smokers, particularly in East Asia, which is expected to increase the global burden of the disease. The classification of non-small cell lung cancer (NSCLC) into distinct subtypes is crucial for treatment efficacy and patient safety, especially as different subtypes respond differently to chemotherapy. For instance, certain chemotherapeutic agents are more effective for adenocarcinoma than for squamous carcinoma, which has led to the exclusion of squamous carcinoma from treatments like Bevacizumab due to safety concerns. This necessitates accurate histological diagnosis, which requires sufficient tissue samples from biopsies. However, acquiring adequate tissue is challenging due to the complex nature of lung tumors, patient comorbidities, and potential complications from biopsy procedures, such as bleeding, pneumothorax, and the purported risk of local recurrence. The need for improved diagnostic techniques has led to the development of advanced technologies like electromagnetic navigation bronchoscopy (ENB), radial endobronchial ultrasound (rEBUS), and robotic bronchoscopy. ENB and rEBUS have enhanced the accuracy and safety of lung biopsies, particularly for peripheral lesions, but both have limitations, such as the dependency on the presence of a bronchus sign. Robotic bronchoscopy, which builds on ENB, offers greater maneuverability and stability, improving diagnostic yields. Additionally, new imaging adjuncts, such as Cone Beam Computed Tomography (CBCT) and augmented fluoroscopy, further enhance the precision of these procedures by providing real-time, high-resolution imaging. These advancements are crucial as lung cancer is increasingly being detected at earlier stages due to screening programs, which require minimally invasive, accurate diagnostic methods to improve patient outcomes. This review aims to provide a comprehensive overview of the current challenges in lung cancer diagnostics and the innovative technological advancements in this rapidly evolving field, which represents an increasingly exciting career path for aspiring pulmonologists.
肺癌是一个重大的全球健康问题,2020年报告的病例数为221万例,死亡人数为180万例。它是全球癌症死亡的主要原因。大多数肺癌与吸烟有关,多年来香烟成分的变化导致了癌症类型和肺部肿瘤位置的转变。此外,从不吸烟者中肺癌的发病率也在不断上升,尤其是在东亚地区,这预计将增加该疾病的全球负担。将非小细胞肺癌(NSCLC)分为不同亚型对于治疗效果和患者安全至关重要,特别是因为不同亚型对化疗的反应不同。例如,某些化疗药物对腺癌比对鳞状细胞癌更有效,这导致出于安全考虑,鳞状细胞癌被排除在贝伐单抗等治疗之外。这就需要准确的组织学诊断,而这需要活检获取足够的组织样本。然而,由于肺肿瘤的复杂性、患者的合并症以及活检程序可能出现的并发症,如出血、气胸和所谓的局部复发风险,获取足够的组织具有挑战性。对改进诊断技术的需求促使了电磁导航支气管镜(ENB)、径向支气管内超声(rEBUS)和机器人支气管镜等先进技术的发展。ENB和rEBUS提高了肺活检的准确性和安全性,特别是对于周围病变,但两者都有局限性,如依赖支气管征的存在。基于ENB的机器人支气管镜具有更大的可操作性和稳定性,提高了诊断率。此外,新的成像辅助设备,如锥形束计算机断层扫描(CBCT)和增强荧光透视,通过提供实时、高分辨率成像进一步提高了这些程序的精度。随着肺癌因筛查项目而越来越多地在早期被检测到,这些进展至关重要,筛查项目需要微创、准确的诊断方法来改善患者的治疗结果。本综述旨在全面概述肺癌诊断当前面临的挑战以及这个快速发展领域中的创新技术进展,这为有抱负的肺科医生提供了一条越来越令人兴奋的职业道路。